Welcome!

News Feed Item

GenMark Diagnostics Reports Fourth Quarter and Year End 2013 Results

GenMark Diagnostics, Inc. (Nasdaq:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today reported financial results for the fourth quarter and year ended December 31, 2013.

Revenues for the quarter ended December 31, 2013 were $6.5 million compared with $9.4 million during the fourth quarter of 2012. The 32% decrease in total fourth quarter revenue was attributable to a decrease in purchases from Natural Molecular Testing Corporation (NMTC) during the current period, which was offset by significant growth in both reagent and instrument revenue from other customers. NMTC accounted for 57% of total revenues in the quarter ended December 31, 2012 and did not account for any revenues in the fourth quarter of 2013. Revenue during the current quarter from the Company’s “Base Business,” which excludes revenues attributable to NMTC, increased by 58% over the prior year period. Reagent revenues for the fourth quarter declined 36% to $5.9 million compared with $9.1 million in the quarter ended December 31, 2012. Fourth quarter reagent revenue from the Company’s Base Business increased year-over-year by 56%. Instrument and other revenues increased by 100% to $0.6 million from $0.3 million in the prior year period, due mainly to sales of XT-8 instruments. The Company placed a total of 38 net new analyzers during the current quarter to bring its total installed base to 413, all in end-user laboratories within the U.S. market.

“2013 was another year of exceptional execution and performance for our Company, both in terms of the growth of our Base Business, as well as the progress we made toward the development of our NexGen system,” stated GenMark’s President & CEO, Hany Massarany.

Gross profit for the quarter ended December 31, 2013 was $2.9 million, or 45% of revenue, compared with a gross profit of $4.7 million, or 50% of revenue for the same period in 2012.

Operating expenses increased $3.9 million to $13.2 million during the fourth quarter of 2013 compared with the fourth quarter of 2012. Research and Development expenses increased $2.2 million due to the Company’s NexGen platform and assay development activities. Sales and Marketing expenses increased $0.9 million mainly due to continued expansion of the Company’s U.S. sales force ahead of the launch of its NexGen system. General and Administrative expenses increased $0.8 million primarily due to a non-recurring charge of $1.6 million to record the impairment of a long-lived intangible asset related to a license which the Company terminated in 2013. On a non-GAAP basis, which excludes the effect of this impairment charge, operating expenses for the fourth quarter of 2013 were $11.6 million.

Loss per share was $0.26 for the fourth quarter of 2013, compared with a loss per share of $0.15 in the fourth quarter of 2012. On a non-GAAP basis, the Company’s loss per share for the fourth quarter of 2013 was $0.21.

The Company ended the year of 2013 with $106.3 million in cash and investments. The Company intends to continue utilizing its cash balances to invest in the development of its NexGen platform and related test menu, and for infrastructure improvements and general corporate purposes.

FISCAL YEAR 2013 RESULTS

Revenue for the year ended December 31, 2013 was $27.4 million, compared to $20.5 million for the prior year, an increase of 34%. Reagent revenue for the current year was $25.3 million, compared to $19.6 million for the prior year, and instrument sales for the current year were $1.7 million compared to $0.5 million for the prior year. The Company’s Base Business grew by 120% for the year ended December 31, 2013 over the previous year.

Gross profit for the year ended December 31, 2013 was $11.5 million, or 42% of revenue, compared with a gross profit of $8.8 million, or 43% of revenue for the prior year. During the current year, the Company reserved $1.2 million of inventory made for NMTC and impaired $0.3 million of manufacturing equipment procured to support NMTC’s previous purchasing volumes. On a non-GAAP basis, which excludes the effect of these NMTC adjustments, gross profit for the year ended December 31, 2013 was $13.0 million, or 47% of revenue.

Operating expenses increased $15.7 million to $46.4 million during the current year compared with the prior year. Research and Development expenses increased $8.5 million in the current year due to the Company’s NexGen platform and assay development activities. Sales and Marketing expenses increased $6.4 million year-over-year mainly due to an increase in the Company’s allowance for doubtful accounts reserve of $2.7 million related to NMTC, and additional sales personnel costs. General and Administrative expenses increased $0.7 million year-over-year due to an impairment charge of $1.6 million related to a license agreement which the Company terminated in late 2013. On a non-GAAP basis, which excludes NMTC-related adjustments and this non-recurring intangible asset impairment charge, operating expenses for the year ended December 31, 2013 were $42.0 million.

Net loss for the year ended December 31, 2013 was $33.6 million, or a $0.95 loss per share, compared to net loss of $22.1 million, or an $0.84 loss per share, for the prior year. On a non-GAAP basis, the loss per share for the year ended December 31, 2013 was $0.82.

INVESTOR CONFERENCE CALL

GenMark will hold a conference call to discuss fourth quarter and year end 2013 results and the outlook for 2014 at 4:30 PM EDT today. The conference call and webcast can be accessed live through the Company’s website under the Investor Relations section and will be archived for future reference. To listen to the conference call, please dial 877-312-5847 (US/Canada) or 253-237-1154 (International) and use the conference ID number 6963720 approximately five minutes prior to the start time.

ABOUT GENMARK DIAGNOSTICS

GenMark Diagnostics is a leading provider of automated, multiplex molecular diagnostic testing systems that detect and measure DNA and RNA targets to diagnose disease and optimize patient treatment. Utilizing GenMark’s proprietary eSensor® detection technology, GenMark’s eSensor® XT-8 system is designed to support a broad range of molecular diagnostic tests with a compact, easy-to-use workstation and self-contained, disposable test cartridges. GenMark currently markets four tests that are FDA cleared for IVD use: Cystic Fibrosis Genotyping Test, Respiratory Viral Panel, Thrombophilia Risk Test, and Warfarin Sensitivity Test. A number of other tests, including HCV Genotyping, 2C19 Genotyping, and 3A4/3A5 Genotyping are available for research use only. For more information, visit www.genmarkdx.com.

SAFE HARBOR STATEMENT

This press release includes forward-looking statements regarding events, trends and business prospects, which may affect our future operating results and financial position. Such statements, including, but not limited to, those regarding and the timely completion of our NexGen system and related assay development projects, are all subject to risks and uncertainties that could cause our actual results and financial position to differ materially. Some of these risks and uncertainties include, but are not limited to, our ability to successfully develop and commercialize our NexGen system and its related test menu, constraints or inefficiencies caused by unanticipated acceleration and deceleration of customer demand, our ability to successfully expand sales of our product offerings outside the United States, and third-party payor reimbursement to our customers, as well as other risks and uncertainties described under the “Risk Factors” in our public filings with the Securities and Exchange Commission. We assume no responsibility to update or revise any forward-looking statements to reflect events, trends or circumstances after the date they are made.

ABOUT NON-GAAP FINANCIAL MEASURES

GenMark’s management believes that non-GAAP financial measures provide meaningful supplemental information regarding the Company’s performance by excluding certain expenses and other items that may not be indicative of core business results. To supplement the Company’s financial results for the fourth quarter and year ended December 31, 2013 presented in accordance with GAAP, GenMark uses the following financial measures defined as non-GAAP by the SEC: non-GAAP cost of revenues, non-GAAP sales and marketing expenses, non-GAAP operating expenses, non-GAAP other income (expense), non-GAAP gross profit, non-GAAP net loss, and non-GAAP loss per share. GenMark’s management does not, nor does it suggest that investors should, consider such non-GAAP financial measures in isolation from, or as a substitute for, financial information prepared and presented in accordance with GAAP. GenMark believes that both management and investors benefit from referring to these non-GAAP financial measures in assessing GenMark’s performance and when planning, forecasting and analyzing future periods. These non-GAAP financial measures also facilitate management’s internal comparisons to GenMark’s historical performance and our competitors’ operating results. GenMark believes these non-GAAP financial measures are useful to investors in allowing for greater transparency with respect to supplemental information used by management in its financial and operational decision making. Further, our reconciliations of non-GAAP to GAAP operating results, which are included on the attached tables, are presented solely to assist a reader in understanding the impact of the various adjustments to our GAAP operating results, individually and in the aggregate, and are not intended to place any undue prominence on our non-GAAP operating results.

 
GENMARK DIAGNOSTICS, INC.
CONSOLIDATED BALANCE SHEETS
(In thousands, except par value)
 
    As of December 31,
2013     2012
Current assets

(Unaudited)

Cash and cash equivalents $ 35,723 $ 51,250
Investments 69,866
Restricted cash 1,343
Accounts receivable - net of allowances of $2,736 and $30 2,859 3,190
Inventories 2,102 1,993
Prepaid expenses and other current assets   552     226  
Total current assets 111,102 58,002
Property and equipment, net 8,591 7,074
Intangible assets, net 1,197 1,832
Restricted cash 758
Other long-term assets   106     1,108  
Total assets $ 121,754   $ 68,016  
Current liabilities
Accounts payable 3,863 2,445
Accrued compensation 3,375 3,076
Loan payable 37 638
Other current liabilities   2,962     3,015  
Total current liabilities 10,237 9,174
Long-term liabilities
Deferred rent 1,601 1,725
Loan payable, net of current portion 63
Other noncurrent liabilities   748     604  
Total liabilities   12,586     11,566  
Stockholders’ equity
Preferred stock, $0.0001 par value; 5,000 authorized, none issued
Common stock, $0.0001 par value; 100,000 authorized; 41,520 and 32,753 shares issued and outstanding as of December 31, 2013 and December 31, 2012, respectively 4 3
Additional paid-in capital 333,363 247,449
Accumulated deficit (224,209 ) (190,566 )
Accumulated other comprehensive loss   10     (436 )
Total stockholders’ equity   109,168     56,450  
Total liabilities and stockholders’ equity $ 121,754   $ 68,016  
 
 
GENMARK DIAGNOSTICS, INC.
CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS
(In thousands, except per share data)
 
    Three Months Ended       Twelve Month Ended
December 31 December 31,
2013     2012 2013     2012
Revenue

(Unaudited)

(Unaudited)

(Unaudited)

Product revenue $ 6,577 $ 9,335 $ 27,204 $ 20,211
License and other revenue   (125 )   108     200     258  
Total revenue 6,452 9,443 27,404 20,469
Cost of revenues   3,521     4,762     15,894     11,640  
Gross profit   2,931     4,681     11,510     8,829  
Operating expenses
Sales and marketing 2,988 2,114 12,818 6,378
General and administrative 3,940 3,063 11,512 10,806
Research and development   6,274     4,099     22,060     13,536  
Total operating expenses   13,202     9,276     46,390     30,720  
Loss from operations   (10,271 )   (4,595 )   (34,880 )   (21,891 )
Other income (expense)
Interest income 304 25 717 42
Interest expense (2 ) (17 ) (19 ) (90 )
Other income (expense)   (649 )   (1 )   583     (16 )
Total other income (expense)   (347 )   7     1,281     (64 )
Loss before income taxes (10,618 ) (4,588 ) (33,599 ) (21,955 )
(Provision) for income taxes   (14 )   (105 )   (44 )   (148 )
Net loss $ (10,632 ) $ (4,693 ) $ (33,643 ) $ (22,103 )
Net loss per share, basic and diluted $ (0.26 ) $ (0.15 ) $ (0.95 ) $ (0.84 )
Weighted average number of shares outstanding, basic and diluted   40,957     31,775     35,253     26,215  
Other comprehensive loss
Net loss $ (10,632 ) $ (4,693 ) $ (33,643 ) $ (22,103 )
Net unrealized gains on available-for-sale investments, net of tax   (16 )       (4 )    
Comprehensive loss $ (10,648 ) $ (4,693 ) $ (33,647 ) $ (22,103 )
 
 
GENMARK DIAGNOSTICS, INC.
UNAUDITED RECONCILIATION OF NON-GAAP FINANCIAL MEASURES
(In thousands, except per share data)
 
    Three Months Ended       Twelve Month Ended
December 31 December 31,
Adjusted Financial Data: 2013     2012 2013     2012
Cost of revenues $ 3,521 $ 4,761 $ 15,894 $ 11,640
Inventory reserve(1) (1,183 )
Impairment of production equipment(2)           (302 )    
Non-GAAP cost of revenues $ 3,521   $ 4,761   $ 14,409   $ 11,640  
 
Gross profit $ 2,930 $ 4,681 $ 11,510 $ 8,829
Inventory reserve(1) 1,183
Impairment of production equipment(2)           302      
Non-GAAP gross profit $ 2,930   $ 4,681   $ 12,995   $ 8,829  
 
Non-GAAP gross margin % 45 % 50 % 47 % 43 %
 
Total operating expenses 13,202 9,276 46,390 30,720
Inventory reserve(1) (19 )
Allowance of doubtful accounts(3) (2,702 )
Impairment of intangible asset(4)   (1,624 )       (1,624 )    
Non-GAAP operating expenses $ 11,578   $ 9,276   $ 42,045   $ 30,720  
 
Total other income (expense) $ (347 ) $ 7 $ 1,281 $ (64 )
Preferred stock sale(5) (9 ) (1,392 )
Elimination of foreign currency translation adjustments upon liquidation of foreign subsidiary(6)   450         450      
Non-GAAP other income (expense) $ 94   $ 7   $ 339   $ (64 )
 
Net loss $

(10,632

)

$

(4,695

)

$ (33,643 ) $ (22,103 )
Inventory reserve(1) 1,202
Impairment of production equipment(2) 302
Allowance of doubtful accounts(3) 2,702
Impairment of intangible asset(4) 1,624 1,624
Preferred stock sale(5) (9 ) (1,392 )
Elimination of foreign currency translation adjustments upon liquidation of foreign subsidiary(6)   450         450      
Non-GAAP net loss $

(8,567

)

$

(4,695

)

$ (28,755 ) $ (22,103 )
 
Net loss per share, basic and diluted $ (0.26 ) $ (0.15 ) $ (0.95 ) $ (0.84 )
Inventory reserve(1) 0.04
Impairment of production equipment(2) 0.01
Allowance of doubtful accounts(3) 0.08
Impairment of intangible asset(4) 0.04 0.03
Preferred stock sale(5) (0.04 )
Elimination of foreign currency translation adjustments upon liquidation of foreign subsidiary(6)   0.01         0.01      
Non-GAAP net loss per share, basic and diluted $ (0.21 ) $ (0.15 ) $ (0.82 ) $ (0.84 )
 

(1) Reflects nonrecurring charges related to inventory specifically made for NMTC

(2) Reflects nonrecurring charges related to the Company’s procurement of additional manufacturing equipment to support NMTC’s prior purchasing patterns

(3) Reflects nonrecurring charges related to outstanding amounts owed by NMTC

(4) Reflects a nonrecurring impairment charge related to the termination of a license agreement

(5)Reflects a nonrecurring realized gain on sale of Advanced Liquid Logic, Inc. preferred stock to Illumina. Inc.

(6) Reflects a nonrecurring accumulated other comprehensive loss realized upon liquidation of foreign subsidiary

The Company makes reference in this release to “non-GAAP” results, which exclude the impact of adjustments associated with NMTC’s bankruptcy, the impairment of an intangible asset, the realization of an accumulated comprehensive loss, and the one-time gain realized upon the sale of the Company’s investment in a private company. The Company believes that excluding these items and their related effects from its financial results reflects operating results that are more indicative of the Company’s ongoing operating performance while improving comparability to prior periods, and, as such, may provide investors with an enhanced understanding of the Company’s past financial performance and prospects for the future. This information is not intended to be considered in isolation from, or as a substitute for, statement of comprehensive loss, net loss, net loss per share or expense information prepared in accordance with GAAP.

 
GENMARK DIAGNOSTICS, INC.
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In thousands)
 
    Year ended December 31,
2013     2012     2011
Operating activities:

(Unaudited)

Net loss $ (33,643 ) $ (22,103 ) $ (23,970 )
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization 2,530 1,198 1,326
Amortization of premiums on investments 314
Stock-based compensation 3,893 2,352 1,872
Provision for bad debt 2,721 (24 )
Non-cash inventory adjustments 1,779 (482 ) 517
Gain on sales of investment in preferred stock (1,392 )
Elimination of cumulative foreign currency translation adjustments upon liquidation of foreign subsidiary 450
Impairment of intangible asset 1,624
Changes in operating assets and liabilities:
Accounts receivable (2,390 ) (2,068 ) (420 )
Inventories (1,313 ) 880 (1,742 )
Prepaid expenses and other current liabilities (119 ) 68 1,846
Accounts payable 1,343 728 378
Accrued compensation 951 1,811 979
Other liabilities   (544 )   1,397      
Net cash used in operating activities   (23,796 )   (16,243 )   (19,214 )
Investing activities
Change in restricted cash 585 (1,343 )
Purchase of available-for-sale securities (76,190 ) (1,000 )
Payments for intellectual property licenses (882 ) (1,327 ) (734 )
Purchases of property and equipment (4,270 ) (3,476 ) (1,376 )
Proceeds from sales of marketable securities and preferred stock 6,643

Maturities (purchases) of short-term investments

  1,550     5,000     (5,000 )
Net cash used in investing activities   (72,564 )   (2,146 )   (7,110 )
Financing activities
Proceeds from issuance of common stock 86,547 48,300 34,533
Cost incurred in conjunction with public offering (5,510 ) (3,211 ) (2,854 )
Proceeds from borrowings 166 991 2,000
Principal repayment of borrowings (766 ) (1,984 ) (417 )
Proceeds from stock exercises   396     223      
Net cash provided by financing activities   80,833     44,319     33,262  
Effects of foreign exchange rate changes           53  
Net (decrease) increase in cash and cash equivalents (15,527 ) 25,930 6,991
Cash and cash equivalents at beginning of period   51,250     25,320     18,329  
Cash and cash equivalents at end of period $ 35,723   $ 51,250   $ 25,320  
Non-cash investing and financing activities:
Property and equipment purchased with capital lease $ $ 109 $
Transfer of systems from property and equipment into inventory $ 575 $ 223 $ 46
Property and equipment costs incurred but not paid included in accounts payable $ 603 $ 592 $ 76
Leasehold improvements related to lease incentives $ $ 1,359 $
Intellectual property acquisition included in other noncurrent liabilities $ 450 $ $
Offering costs incurred but not paid included in other liabilities 65
Supplemental cash flow disclosures:
Cash paid for interest $ 19 $ 90 $ 95
Cash received for interest $ 717 $ 42 $ 21
Cash received for income taxes, net $ 2 $ $ 3
Cash paid for income taxes $ 21 $ 91 $
 

More Stories By Business Wire

Copyright © 2009 Business Wire. All rights reserved. Republication or redistribution of Business Wire content is expressly prohibited without the prior written consent of Business Wire. Business Wire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
Bill Schmarzo, author of "Big Data: Understanding How Data Powers Big Business" and "Big Data MBA: Driving Business Strategies with Data Science," is responsible for setting the strategy and defining the Big Data service offerings and capabilities for EMC Global Services Big Data Practice. As the CTO for the Big Data Practice, he is responsible for working with organizations to help them identify where and how to start their big data journeys. He's written several white papers, is an avid blogge...
"We are a well-established player in the application life cycle management market and we also have a very strong version control product," stated Flint Brenton, CEO of CollabNet,, in this SYS-CON.tv interview at 18th Cloud Expo at the Javits Center in New York City, NY.
DXWorldEXPO LLC announced today that Dez Blanchfield joined the faculty of CloudEXPO's "10-Year Anniversary Event" which will take place on November 11-13, 2018 in New York City. Dez is a strategic leader in business and digital transformation with 25 years of experience in the IT and telecommunications industries developing strategies and implementing business initiatives. He has a breadth of expertise spanning technologies such as cloud computing, big data and analytics, cognitive computing, m...
One of the biggest challenges with adopting a DevOps mentality is: new applications are easily adapted to cloud-native, microservice-based, or containerized architectures - they can be built for them - but old applications need complex refactoring. On the other hand, these new technologies can require relearning or adapting new, oftentimes more complex, methodologies and tools to be ready for production. In his general session at @DevOpsSummit at 20th Cloud Expo, Chris Brown, Solutions Marketi...
At the keynote this morning we spoke about the value proposition of Nutanix, of having a DevOps culture and a mindset, and the business outcomes of achieving agility and scale, which everybody here is trying to accomplish," noted Mark Lavi, DevOps Solution Architect at Nutanix, in this SYS-CON.tv interview at @DevOpsSummit at 20th Cloud Expo, held June 6-8, 2017, at the Javits Center in New York City, NY.
HyperConvergence came to market with the objective of being simple, flexible and to help drive down operating expenses. It reduced the footprint by bundling the compute/storage/network into one box. This brought a new set of challenges as the HyperConverged vendors are very focused on their own proprietary building blocks. If you want to scale in a certain way, let's say you identified a need for more storage and want to add a device that is not sold by the HyperConverged vendor, forget about it...
Enterprises are moving to the cloud faster than most of us in security expected. CIOs are going from 0 to 100 in cloud adoption and leaving security teams in the dust. Once cloud is part of an enterprise stack, it’s unclear who has responsibility for the protection of applications, services, and data. When cloud breaches occur, whether active compromise or a publicly accessible database, the blame must fall on both service providers and users. In his session at 21st Cloud Expo, Ben Johnson, C...
It is of utmost importance for the future success of WebRTC to ensure that interoperability is operational between web browsers and any WebRTC-compliant client. To be guaranteed as operational and effective, interoperability must be tested extensively by establishing WebRTC data and media connections between different web browsers running on different devices and operating systems. In his session at WebRTC Summit at @ThingsExpo, Dr. Alex Gouaillard, CEO and Founder of CoSMo Software, presented ...
In this presentation, you will learn first hand what works and what doesn't while architecting and deploying OpenStack. Some of the topics will include:- best practices for creating repeatable deployments of OpenStack- multi-site considerations- how to customize OpenStack to integrate with your existing systems and security best practices.
As you move to the cloud, your network should be efficient, secure, and easy to manage. An enterprise adopting a hybrid or public cloud needs systems and tools that provide: Agility: ability to deliver applications and services faster, even in complex hybrid environments Easier manageability: enable reliable connectivity with complete oversight as the data center network evolves Greater efficiency: eliminate wasted effort while reducing errors and optimize asset utilization Security: implemen...
Your homes and cars can be automated and self-serviced. Why can't your storage? From simply asking questions to analyze and troubleshoot your infrastructure, to provisioning storage with snapshots, recovery and replication, your wildest sci-fi dream has come true. In his session at @DevOpsSummit at 20th Cloud Expo, Dan Florea, Director of Product Management at Tintri, provided a ChatOps demo where you can talk to your storage and manage it from anywhere, through Slack and similar services with...
Most people haven’t heard the word, “gamification,” even though they probably, and perhaps unwittingly, participate in it every day. Gamification is “the process of adding games or game-like elements to something (as a task) so as to encourage participation.” Further, gamification is about bringing game mechanics – rules, constructs, processes, and methods – into the real world in an effort to engage people. In his session at @ThingsExpo, Robert Endo, owner and engagement manager of Intrepid D...
Recently, WebRTC has a lot of eyes from market. The use cases of WebRTC are expanding - video chat, online education, online health care etc. Not only for human-to-human communication, but also IoT use cases such as machine to human use cases can be seen recently. One of the typical use-case is remote camera monitoring. With WebRTC, people can have interoperability and flexibility for deploying monitoring service. However, the benefit of WebRTC for IoT is not only its convenience and interopera...
Evan Kirstel is an internationally recognized thought leader and social media influencer in IoT (#1 in 2017), Cloud, Data Security (2016), Health Tech (#9 in 2017), Digital Health (#6 in 2016), B2B Marketing (#5 in 2015), AI, Smart Home, Digital (2017), IIoT (#1 in 2017) and Telecom/Wireless/5G. His connections are a "Who's Who" in these technologies, He is in the top 10 most mentioned/re-tweeted by CMOs and CIOs (2016) and have been recently named 5th most influential B2B marketeer in the US. H...
Michael Maximilien, better known as max or Dr. Max, is a computer scientist with IBM. At IBM Research Triangle Park, he was a principal engineer for the worldwide industry point-of-sale standard: JavaPOS. At IBM Research, some highlights include pioneering research on semantic Web services, mashups, and cloud computing, and platform-as-a-service. He joined the IBM Cloud Labs in 2014 and works closely with Pivotal Inc., to help make the Cloud Found the best PaaS.